Incorporating New Therapeutic Strategies in the Treatment of Hodgkin Lymphoma
Source: Incorporating New Therapeutic Strategies in the Treatment of Hodgkin Lymphoma

Video Module

In this on-demand Webcast of a CCO symposium at ASH 2017, Ranjana Advani, MD, leads an expert panel with Robert W. Chen, MD; Andrew Evens, DO, MSc, FACP; and Pier Luigi Zinzani, MD, PhD, as they review and discuss the latest clinical strategies for managing patients with Hodgkin lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess the results of recent trials of response-adapted frontline therapy in Hodgkin lymphoma and how they will influence clinical practice
  • Choose optimal intensified frontline treatments for patients with advanced Hodgkin lymphoma, incorporating available and emerging treatment options
  • Describe the application and limitations of FDG-PET imaging in the early assessment of response to treatment in Hodgkin lymphoma
  • Plan therapeutic strategies to prevent second relapse after transplantation in patients with Hodgkin lymphoma at risk of progression
  • Evaluate the clinical data on available and promising investigational agents for patients with relapsed/refractory Hodgkin lymphoma
  • Determine optimal sequencing of brentuximab vedotin and immune checkpoint inhibitors in the treatment of patients with Hodgkin lymphoma
CCO Video Modules contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
 

Program Directors

  • Ranjana Advani
    MD

Faculty

  • Robert W. Chen
    MD
    Andrew M. Evens
    DO, MSc, FACP
    Pier Luigi Zinzani
    MD, PhD

Credit Information

  • Release Date:
    January 24, 2018
  • Expiration Date:
    January 23, 2019
  • Physicians:
    maximum of 2.0 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

 

Program Directors

Ranjana Advani, MD

Professor of Medicine
Department of Oncology
Stanford University Medical Center
Stanford Cancer Center
Stanford, California

Ranjana Advani, MD, has disclosed that she has received consulting fees from Bayer, Bristol-Myers Squibb, Cell Medica, Genentech/Roche, Gilead Sciences, Juno, NanoString, Pharmacyclics, Spectrum, and Sutro and funds for research support from Agensys, Bristol-Myers Squibb, Celgene, Forty Seven Inc, Genentech/Roche, Janssen, Infinity, Kura, Merck, Millennium, Pharmacyclics, Regeneron, and Seattle Genetics.

 

Faculty

Robert W. Chen, MD


Associate Professor
Department of Hematology
City of Hope
Duarte, California

Robert W. Chen, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Genentech, Merck, and Seattle Genetics and funds for research support from Bristol-Myers Squibb, Pharmacyclics, and Seattle Genetics.

 

Andrew M. Evens, DO, MSc, FACP


Professor and Chief
Division of Hematology/Oncology
Tufts Medical Center
Boston, Massachusetts

Andrew M. Evens, DO, MSc, FACP, has disclosed that he has received consulting fees from AbbVie, Affimed, Amgen, Celgene, Kite Pharma, Merck, Millennium, Novartis, Pharmacyclics, Seattle Genetics, and Spectrum; fees for non-CME/CE services from Celgene; and funds for research support from Millennium/Takeda and Seattle Genetics.

 

Pier Luigi Zinzani, MD, PhD


Professor of Hematology
Chief of Lymphoma and CLL Unit
Institute of Hematology "Seràgnoli"
University of Bologna
Bologna, Italy

Pier Luigi Zinzani, MD, PhD, has disclosed that he has received consulting fees from Astellas, Bristol-Myers Squibb, Celgene, Gilead Sciences, Janssen, Lundbeck, Merck, Mundipharma, Nordic Nanovector, Roche, Sandoz, Servier, Takeda, and Verastem.

 

Staff

Megan Cartwright, PhD


Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

 

Timothy A. Quill, PhD


Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

 

Kevin Obholz, PhD


Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with Hodgkin lymphoma.


Goal

The goal of this activity is to improve participants’ competence in and performance at selecting treatment for individual patients with Hodgkin lymphoma.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess the results of recent trials of response-adapted frontline therapy in Hodgkin lymphoma and how they will influence clinical practice
  • Choose optimal intensified frontline treatments for patients with advanced Hodgkin lymphoma, incorporating available and emerging treatment options
  • Describe the application and limitations of FDG-PET imaging in the early assessment of response to treatment in Hodgkin lymphoma
  • Plan therapeutic strategies to prevent second relapse after transplantation in patients with Hodgkin lymphoma at risk of progression
  • Evaluate the clinical data on available and promising investigational agents for patients with relapsed/refractory Hodgkin lymphoma
  • Determine optimal sequencing of brentuximab vedotin and immune checkpoint inhibitors in the treatment of patients with Hodgkin lymphoma
 

Physician Continuing Medical Education

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by educational grants from Merck & Co., Inc., Takeda Oncology, and Seattle Genetics.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 24, 2018, through January 23, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.